REDWOOD CITY, Calif.--(BUSINESS WIRE)--Global law firm Goodwin announced today that Shane Albright has joined the firm’s Silicon Valley office as partner in its Life Sciences practice, expanding the firm’s resources and offering in Northern California.
Albright represents life science companies in a wide range of corporate, financial and commercial matters, with a particular emphasis on complex transactions involving intellectual property. He has extensive experience counseling clients on corporate partnering issues, strategic alliances, technology licenses and key commercial contracts, such as manufacturing and distribution agreements. Albright also represents emerging growth companies and their investors in venture financings, other funding transactions and general corporate matters. His clients include companies in the biopharmaceutical, medical device, diagnostics, hardware, software, medical instrumentation, digital health, vaccine and research reagent spaces, as well as entities that fund or conduct medical research.
“Goodwin has developed a leading international life sciences practice, which cutting-edge biotech companies continually engage to help guide them through formation to strategic collaborations and exits, and everything in between,” said Mitchell Bloom, Co-Chair of Goodwin’s Life Sciences Practice. “Shane’s vast experience handling complex licensing transactions, mergers and acquisitions, and initial public offerings complements our existing bench and expansion efforts on the West Coast. We are thrilled that he has chosen to join our firm.”
Albright said, “Goodwin has a well-deserved reputation for handling some of the most complex and innovative transactions in the life sciences space. I am excited to join the team and looking forward to leveraging the Goodwin platform to help my clients develop and monetize their cutting-edge drugs and medical technologies.”
Albright received his J.D. from Stanford University Law School and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. He is admitted to practice in California and has been recognized as a “Life Sciences Star” by LMG Life Sciences. Albright is also a frequent speaker on issues relating to licensing and corporate partnering.
He can be reached at firstname.lastname@example.org and on 650.752 3219.
Goodwin’s Life Sciences practice was named “Practice Group of the Year” for the past two years by Law360, which called Goodwin “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” The firm has also been recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year” for five out of last six years and as the “2017 IP Law Firm of the Year” by LMG Life Sciences.
In 2018 to date, Goodwin has represented fifteen biotechnology companies on their public offerings with a collective value close to $1.5 billion.
At Goodwin, we use law to achieve unprecedented results for our clients. Our 1,000 plus lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigations and world-class advisory services in the financial, private equity, real estate, and technology industries. We partner with our life sciences clients to practice law with integrity, ingenuity, agility and ambition. To learn more, visit us at www.goodwinlaw.com and follow us on Twitter, LinkedIn and Instagram.